Hepatitis C Virus (HCV) infection Infections and Infestations Chronic viral hepatitis
Conditions
Interventions
In stage 1, we will investigate the physiologic response to pioglitazone therapy by comparing measured total insulin resistance, hepatic insulin resistance, interferon sensitivity and virologic respon
Sponsors
Imperial College London and Imperial College Healthcare NHS Trust (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Chronic HCV genotype 1 infection 2. Chronic HCV and compensated liver cirrhosis who failed to respond to previous treatment 3. Age >17, <70 4. Eligible for interferon therapy
Exclusion criteria
Exclusion criteria: 1. HIV or HBV co-infection 2. Current use antidiabetic medication (e.g., insulin, metformin or thiazolidinedione) 3. Significant respiratory, cardiac or renal dysfunction 4. Body Mass Index > 30 kg/m2
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Insulin resistance: Total body insulin resistance and hepatic insulin resistance will be measured using the hyperinsulinaemic euglycaemic clamp. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Interferon sensitivity (Interferon-Inducible Protein [IP10] in blood measured by ELISA and in peripheral blood mononuclear cells [PBMC] by mRNA) 2. Viral dynamic response measured by serial HCV PCR levels 3. Treatment response measured by serial HCV PCR levels | — |
Countries
United Kingdom
Outcome results
None listed